Archynetys Live news trend intelligence
◼ Archived Business 🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct

McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports

A $5.8 billion deal to take Option Care private signals a major consolidation push in health‑care infusion services.

4sources
5articles
3velocity
+0%since first seen
46d agofirst detected
Text:
🤖 AI Dossier

Evidence dossier

Intelligence passport

40/100 Publishable
4distinct sources shown
40velocity measurements
1language editions checked
Unsupported statements were removed before publicationbrief evidence status

Measured timeline

  1. Detected

  2. Latest coverage observed

  3. Peak measured velocity

  4. Evidence threshold reached

  5. Outcome review added

Momentum

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The story so far

⚡ Executive Intelligence Takeaways Corroborated across 4 independent newsrooms
  • Velocity & Diffusion: Coverage exploded across 4 distinct news outlets with 5 published articles, achieving a live velocity of 3.
  • Primary Driver: A $5.8 billion deal to take Option Care private signals a major consolidation push in health‑care infusion services.
  • Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
  • Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.

A $5.8 billion acquisition was announced for infusion‑therapy provider Option Care, pricing the deal at $32.05 per share. The transaction pairs pharmacy giant McKesson with private‑equity firm Clayton, Dubilier & Rice (CD&R) as co‑buyers.

The coverage places the transaction among the largest health‑care buyouts this year, alongside Energy Transfer’s $2.6 billion purchase of Vaquero, highlighting a wave of multi‑billion deals in the sector. Regulatory approval and financing steps are expected to follow.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 44d ago.

Who reported it (5)

The obvious questions

What is the purchase price and per‑share amount for Option Care?

The acquisition values Option Care at $5.8 billion, or $32.05 per share.

Who are the acquiring parties in the transaction?

Pharmacy distributor McKesson and private‑equity firm Clayton, Dubilier & Rice (CD&R) are the co‑buyers.

What is the current status of the deal?

Reuters reports the deal is described as near $5 billion‑plus and moving toward finalisation, based on an FT report.

📊 AUDIENCE & LONGEVITY PULSE

How do you expect this trend to evolve over the next 24 hours?

Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.

Topics

McKesson CD&R Option Care infusion therapy health‑care M&A

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →